Video-Tumorboard PLUS

Recruiting

• Conditions: Malignant Melanoma; Telemedicine

• Registration Number: NCT06980740
• Lead Sponsor: University Hospital Muenster

Brief Summary

In weekly expert meetings for oncological diagnostics and therapy, known as tumor boards, individual therapy recommendations are developed for cancer patients. By further developing and optimizing the CCCs' video tumor boards, initially using skin cancer as an example, we want to ensure that more patients can benefit from the expertise of several specialist disciplines and innovations - regardless of where they live.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-04
• Study First Submitted: 2025-04-16
• Study Start: 2025-05-01
• Study First Submitted QC: 2025-05-16
• Last Update Submitted: 2025-05-16
• Study First Posted: 2025-05-20
• Last Update Posted: 2025-05-20
• Primary Completion: 2026-05-31
• Study Completion: 2027-05-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• The study includes adult, external patients who, according to the certification requirements of the German Cancer Society, should be presented to the CCCs in a tumor board .

Inclusion criteria for patients:

• Minimum age 18 years

• Consent to participate in the study (signing of patient consent) should be presented in vTB+ according to the doctor, based on the disease/diagnosis, especially in the case of:

  • Malignant melanoma from stage IIB
  • Malignant melanoma and stage shift/recurrence o Extracutaneous melanoma o Cutaneous lymphoma from stage Ib o Problem cases with malignant, epithelial tumors (BCC, SCC) with interdisciplinary issues, e.g. complicated localization, extension/ infiltration (e.g. Ulcus rodens, Ulcus terebrans), metastasized tumors, immunosuppressed patients o all rare malignant skin tumors (including Merkel cell carcinoma, DFSP, MFH, leiomyosarcoma, S., Kaposi's sarcoma, angiosarcoma), regardless of stage o severe side effects from drug-based tumor therapy • is an external patient: An external patient is someone who receives tumor therapy exclusively or in co-treatment in the branch or in an external clinic (in distinction to patients without prior treatment for initial presentation at the CCC) . This also applies to patients who are only seen once at the vTB.

In this case, revenue/cost aspects and the DKG requirement are ignored. This means that so-called external patients can also be treated at the center, including initiation of therapy. The decisive factor is the presentation of the external patient (personal presentation of the external patients is not mandatory) and that external co-treaters are consistently informed and involved.

Inclusion criteria for external doctors:

• has a medical license
• has dermatological patients who are eligible to be presented in the vTB+

Exclusion Criteria

Patients will be excluded from the study if they meet the following criteria:

• Linguistic or other limitations (such as dementia) that prevent independent consent to the privacy policy.
• No consent to participate in the study (patient consent) or withdrawal of consent during the course of the study In addition, external physicians will be excluded from the study if no joint cooperation agreement can be negotiated and signed.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Presentation of external patients in the video-tumorboard	Day 365	Increase in the proportion of external patients in the video-tumorboard

Secondary Outcome Measures

Name	Time	Method
Increase in the proportion of external patients invited to a clinical study	Day 365	Increase in the proportion of external patients in clinical studies
Adherence to tumorboard recommendations for external patients	Up to two weeks after inclusion	Proportion of implemented tumorboard recommendations for external patients
Offer of supportive therapies by the comprehensive cancer center	Up to two days after inclusion	Proportion of (external) patients who are offered at least one supportive therapy (e.g. psychooncology) within the video-tumorboard
Duration of the transmission of the tumorboard recommendations	Up to two weeks after inclusion	Duration of the transmission of the tumorboard recommendations
"Time to integration" into palliative care	Once per patient within two weeks after transmission of the tumorboard recommendation if applicable	Time between medical recommendation for palliative care and first contact with palliative care

Trial Locations

Locations (3)

Abteilung für Integrierte Onkologie - CIO Bonn, Universitätsklinikum Bonn; 🇩🇪 Bonn, Germany

Nationales Centrum für Tumorerkrankungen Klinik u. Poliklinik für Dermatologie, Universitätsklinikum Dresden; 🇩🇪 Dresden, Germany

Westdeutsches Tumorzentrum Münster, Universitätsklinikum Münster; 🇩🇪 Münster, Germany